All In Biotech

BLA 761128 · Novartis Pharms Corp

Adakveo

Crizanlizumab-Tmca · Injection · Selectin Blocker

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jun 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Nov 15, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

14

2 Phase 3, 3 recruiting

FAERS reports

1,397

759 serious, 55 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 4, 2026.

ADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. ADAKVEO is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.

Mechanism: Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands, including P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab can also dissociate preformed P-selectin/PSGL-1 complex. Binding P-selectin on the surface of the activated endothelium and platelets blocks interactions between endothelial cells, platelets, red blood cells, and leukocytes.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 26, 2024 Supplement 6 · Efficacy OrphanLetterLabel
  • Nov 15, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • ADAKVEO · CRIZANLIZUMAB-TMCA 100MG/10ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Crizanlizumab" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • sickle cell anaemia with crisis364
  • pain353
  • back pain151
  • infusion related reaction131
  • arthralgia95
  • pain in extremity89
  • chest pain81
  • nausea80
  • drug ineffective79
  • pyrexia76
  • headache71
  • fatigue68

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20194
2020343
2021426
2022331
2023114
2024113
202545
202621

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Adakveo (Crizanlizumab-Tmca)

2024 spending

$5.0M

Beneficiaries

85

476 claims

Per beneficiary

$58,308

$240.46 per unit

View as table
YearSpending
2020$5,098,451
2021$5,852,210
2022$6,859,658
2023$6,747,857
2024$4,956,211

Part B: Adakveo (Crizanlizumab-Tmca) · HCPCS J0791

2024 spending

$26.0M

Beneficiaries

419

2,703 claims

Per beneficiary

$62,060

2024 ASP limit $127.59 per unit

View as table
YearSpending
2020$13,054,000
2021$31,071,224
2022$31,259,411
2023$29,665,792
2024$26,003,300

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.